In summary, whilst OGT inhibitors currently lack specificity and selectivity, improvements in OGT inhibitors is necessary to be able to reduce protein O-GlcNAc levels and represents a potentially huge opportunity to reduce cancer or diabetes burden. The gene discussed is OGT; the disease is cancer.